Skip to main
NBIX

Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences (NBIX) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 45%
Buy 41%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Neurocrine Biosciences is well-positioned with a diverse portfolio of treatments in various stages of development, strong governance, and promising results from their phase II trial for a potential antidepressant. While there is potential for growth, challenges such as competition and regulation may affect the stock's performance. However, they are rated as a Buy and have a positive outlook with potential for higher growth if sales exceed expectations.

Bears say

Neurocrine Biosciences is a biopharmaceutical company that focuses on research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Despite a strong product portfolio and potential for future growth with upcoming pipeline catalysts, the company has faced recent challenges such as a recent stock pullback, competition in the market, and a potential slow uptake in initial market adoption. As a result, there are concerns about the sustainability and potential downside risks for the company's stock.

Neurocrine Biosciences (NBIX) has been analyzed by 22 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 41% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neurocrine Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neurocrine Biosciences (NBIX) Forecast

Analysts have given Neurocrine Biosciences (NBIX) a Buy based on their latest research and market trends.

According to 22 analysts, Neurocrine Biosciences (NBIX) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $202.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $202.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neurocrine Biosciences (NBIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.